ReviewArchives of endocrinology and metabolism2025
Subclinical primary aldosteronism.
Review in Archives of endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Subclinical primary aldosteronism: toward a conceptual framework linking primary aldosteronism and low-renin hypertension.Frontiers in endocrinology · 2026Review
- Voices of endocrinology: contemporary insights in endocrine and metabolic disorders.Archives of endocrinology and metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary aldosteronism (PA) is a major contributor to hypertension and cardiovascular disease. Subclinical PA, a preclinical or early manifestation of PA, has been identified in individuals with normal blood pressure and in those with mild hypertension without signs or symptoms of overt PA, using evidence from histopathology, hormonal biochemistry, proteomic, and genetic studies. Longitudinal studies have shown that subclinical PA increases the risk for developing incident hypertension, adverse cardiovascular remodeling, major adverse cardiovascular events, and chronic kidney disease. Given the clinical relevance of subclinical PA on the pathogenesis of cardiorenal disease, future studies should focus on methods to enhance early detection and assessment of the impact of early aldosterone-directed interventions for preventing adverse clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.